Maxpro News Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination Posted on 2022-10-072023-05-29 by maxproadmin More >>
Maxpro News Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp. Posted on 2022-09-142022-11-24 by maxproadmin More >>
Arthrosi Arthrosi completes AR882 phase 2B study enrollment Posted on 2022-08-232022-11-24 by maxproadmin More >>
Acepodia Acepodia Raises $109 Million Series C Financing to Advance Development of First-in-Class Antibody Cell Effector Therapies Posted on 2021-12-022022-09-15 by maxproadmin More >>
Maxpro News Maxpro Capital Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants Posted on 2021-11-262021-12-09 by maxproadmin More >>
ACT Genomics ACT Genomics joins force with Sanomics Posted on 2021-11-222021-12-09 by maxproadmin More >>
SyneuRx SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing Posted on 2021-11-192021-12-09 by maxproadmin More >>
Acepodia Acepodia Strengthens Board of Directors and Scientific Advisory Board with Key Appointments Posted on 2021-11-032021-12-09 by maxproadmin More >>
Arthrosi Arthrosi Presents AR882 Posters at ACR 2021 Posted on 2021-11-022021-11-03 by maxproadmin More >>
EirGenix EIRGENIX COMPLETED ITS NTD 5.03 BILLION PRIVATE PLACEMENT ON THE FIFTEENTH OF OCTOBER Posted on 2021-10-152021-11-03 by maxproadmin More >>